Company: MDCXW
Filing Date: 2025-05-27
Form Type: S-1
Source: 0001062993-25-010333
Chunk: 200

Company: Medicus Pharma Ltd.
Filing Date: 2025-05-27
Form: S-1
Chunk 200
---
 any transaction that establishes a net short position with respect to the common shares. The SEPA stipulates that the Selling Shareholder may sell "long" and may sell our common shares to be issued pursuant to an Advance Notice, following receipt of such Advance Notice, but prior to receiving such shares.

Effect of Sales of Our Common Shares under the SEPA on Our Shareholders

All common shares that may be issued or sold by us to the Selling Shareholder under the SEPA that are being registered under the Securities Act for resale by the Selling Shareholder in this offering are expected to be freely tradable. The common shares being registered for resale in this offering may be issued and sold by us to the Selling Shareholder from time to time at our discretion over the term of the SEPA. The resale by the Selling Shareholder of a significant amount of common shares registered for resale in this offering at any given time, or the perception that these sales may occur, could cause the market price of our common shares to decline and to be highly volatile. Sales of our common shares, if any, to the Selling Shareholder under the SEPA will depend upon market conditions and other factors to be determined by us. We may ultimately decide to sell to the Selling Shareholder all, some, or none of the common shares that may be available for us to sell to the Selling Shareholder pursuant to the SEPA.

<div align='center'>- 133 -</div>

If and when we do elect to sell our common shares to the Selling Shareholder pursuant to the SEPA, the Selling Shareholder may resell all, some, or none of such shares in its discretion and at different prices subject to the terms of the SEPA. As a result, investors who purchase shares from the Selling Shareholder in this offering at different times will likely pay different prices for those shares, and so may experience different levels of dilution and, in some cases, substantial dilution and different outcomes in their investment results. Investors may experience a decline in the value of the shares they purchase from the Selling Shareholder in this offering as a result of future sales made by us to the Selling Shareholder at prices lower than the prices such investors paid for their shares in this offering. In addition, if we sell a substantial number of shares to the Selling Shareholder under the SEPA, or if investors expect that we will do so, the actual sales of shares or the mere existence of our arrangement with the Selling Shareholder may make it more difficult for us to sell equity or equity